Xoma Royalty Corporation · NASDAQ:XOMA
Xoma Royalty — Investor Presentation (May 2023)
23 slides from Xoma Royalty's investor presentation, May 2023
Slide 1: Corporate Presentation: The Royalty Aggregator for Biotech Companies
CORPORATE PRESENTATION THE ROYALTY AGGREGATOR FOR BIOTECH NASDAQ: XOMA COMPANIES MAY 2023
Slide 2: Disclaimers
DISCLAIMERS Certain statements in this presentation are forward-looking SEC filings. Consider such risks carefully when considering XOMA's statements within the meaning of Section 27A of the Securities Act of prospects. Any forward-looking statements represent XOMA’s views 1933 and Section 21E of th
Slide 3: Opportunities Abound for Royalty Monetization
OPPORTUNITIES ABOUND FOR ROYALTY MONETIZATION License LIFE SCIENCES INDUSTRY LICENSING DEALS ANNUALLY transactions 2014 – 2021 consist of: ▪ Upfront payment 645 648 620 ▪ Milestone payments 585 522 548 ▪ Royalty obligations 459 404 2014 2015 2016 2017 2018 2019 2020 2021 Bloomberg data 3
Slide 4: We Buy
WE BUY: & 4
Slide 5: XOMA's Ideal Asset
XOMA’S IDEAL ASSET STRONG DEVELOPER/MARKETER Assets partnered with high-quality pharma / biopharma companies MID- TO EARLY-STAGE CLINICAL ASSETS Rx Therapeutic area agnostic LONG DURATION OF MARKET EXCLUSIVITY Patent expiration or regulatory exclusivity HIGH REVENUE POTENTIAL High unmet need or clea
Slide 6: Basics of a XOMA Royalty Monetization Transaction
BASICS OF A XOMA ROYALTY MONETIZATION TRANSACTION STEP 1: STEP 2: Capital BIOTECH Royalties & Milestones Program Royalties & Licensed Milestones BIG PHARMA 6
Slide 7: Actively Acquiring New Royalties
ACTIVELY ACQUIRING NEW ROYALTIES SELLER PARTNER / LICENSEE ASSETS ACQUIRED CAPITAL DEPLOYED THERAPEUTIC AREA or INDICATION(s) Aptevo 1 $9.6M Hemophilia B $14M wAMD, DME, other retinal Affitech 1 ($6M upfront, $5M on FDA approval, $3M on EU approval) conditions ObsEva 1 $15M Preterm labor Viracta 2 $
Slide 8: Ixinity Transaction
IXINITY TRANSACTION: ® $9.6M outlay to Aptevo Mid-single digit royalties on sales beginning 1/1/2023 into 1Q2035 Marketed in the U.S. by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B 8
Slide 9: Ebopiprant Transaction
EBOPIPRANT TRANSACTION: $15M outlay to ObsEva $378M potential milestones Mid-single to low-teens royalty, net Organon secured development & commercialization license from ObsEva in July 2021 “This development-stage asset is being studied in one of the most crucial unmet needs for women globally. As
Slide 10: XOMA Is Differentiated in Royalty Monetization
XOMA IS DIFFERENTIATED IN ROYALTY MONETIZATION Capital per transaction $200M + Royalty Pharma $100M – DRI $200M Healthcare Trust $25M – FOCUSED ON Ligand $100M MID- TO EARLY-STAGE CLINICAL ASSETS HCRP < $25M PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL COMMERCIAL 10
Slide 11: Royalty Monetization - Increasingly in Focus
ROYALTY MONETIZATION - INCREASINGLY IN FOCUS 11
Slide 12: Royalty Monetization Increasingly More Attractive
ROYALTY MONETIZATION INCREASINGLY MORE ATTRACTIVE Source: The Brookline Brief, November 2, 2022 12
Slide 13: XOMA Snapshot: Portfolio of 70+ Assets
XOMA SNAPSHOT Portfolio of ▪ Acquire drug royalties + milestones associated with mid- to early-stage clinical candidates 70+ ASSETS – Differentiate by focusing on development-stage assets in >30 disclosed indications with blockbuster potential licensed to large-cap partners today and growing ▪ Provi
Slide 14: Key XOMA Portfolio Assets
KEY XOMA PORTFOLIO ASSETS https://www.xoma.com/portfolio 14
Slide 15: XOMA's Broad Portfolio Without Spend
XOMA’S BROAD PORTFOLIO WITHOUT SPEND COMMERCIALIZED PHASE 3 PHASE 2 Further Development 2 Assets 3 Assets 26Assets Expenses by XOMA: PHASE 1/2 PHASE 1 PRECLINICAL $0 2 16 15+ >50% of assets with Large-cap partners Assets Assets Assets 15
Slide 16: Since 2017, XOMA's Portfolio Continues to Advance and Mature
SINCE 2017, XOMA’S PORTFOLIO CONTINUES TO ADVANCE AND MATURE PHASE 3 TO APPROVAL 1 PHASE 2 TO PHASE 3 4 PHASE 2A TO PHASE 2B 2 PHASE 1 TO PHASE 2 11 30 Advancements PHASE → PHASE ENTERED CLINIC 12 PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL 16
Slide 17: 2023: Potential Events from Our Partners
2023: POTENTIAL EVENTS FROM OUR PARTNERS S PO N S O R/ PROGRAM: Phase 1 Phase 2 Phase 3 Regulatory Medexus / IXINITY Label Expansion Day One / tovorafenib Ph 2 pediatric low-grade glioma readout Ph 3 initiation Est 2023 NDA filing Rezolute / RZ358 Ph 2 completed - CHI readout Ph 3 initiation Ph 3 BC
Slide 18: Who We Are
WHO WE ARE Board of Directors ▪ Leadership ▪ Owen Hughes, Executive Chair XOMA – Owen Hughes, Executive Chair ▪ Heather L. Franklin – Brad Sitko, Chief Investment Officer Blaze BioScience – Tom Burns, Chief Financial Officer ▪ Natasha Hernday Seagen ▪ Business Development Team ▪ Barbara Kosacz Krono
Slide 19: Financial Highlights
FINANCIAL HIGHLIGHTS ($M) $100 Y/E Cash $90 $80 Expenses >$94M $70 in milestone $60 payments $50 since 2016 $40 $30 ~$1.5B $20 in potential $10 milestones $0 2016 2017 2018 2019 2020 2021 2022 19
Slide 20: Roche's VABYSMO approved in US, EU, Japan
Regulatory agencies in US, EU, Japan, others have granted commercialization approval to Roche’s VABYSMO® (faricimab) XOMA received >$2.9M on sales through 12/31/22 THE FIRST ASSET UNDER XOMA’S ROYALTY AGGREGATOR BUSINESS MODEL TO BE APPROVED Acquired economic rights from Affitech SA 20
Slide 21: What Makes XOMA So Exciting
WHAT MAKES XOMA SO EXCITING ▪ XOMA’s model demonstrates future potential through cash from commercial sales ‒ >$2.9M cash received from Roche’s VABYSMO®1 sales through 12/31/22 ‒ Cash from IXINITY® sales begin 1Q23 ▪ Potential royalty stream on 70+ assets; pharmaceutical partners fund 100% of resear
Slide 22: Corporate Presentation: The Royalty Aggregator for Biotech Companies
CORPORATE PRESENTATION THE ROYALTY AGGREGATOR FOR BIOTECH NASDAQ: XOMA COMPANIES MAY 2023
Slide 23: A Significant Number of Partner-Driven Clinical Events Achieved in 2021 & 2022
A SIGNIFICANT NUMBER OF PARTNER-DRIVEN CLINICAL EVENTS ACHIEVED IN 2021 & 2022 As disclosed by partners in public filings PHASE 1 PHASE 1/2 PHASE 2 PHASE 3 REGULATORY ▪ Bayer/osocimab: ▪ Incyte/INCAGN01876: Advanced Rezolute/RZ358: ▪ Novartis/NIS793: ▪ Roche/VABYSMO® ESRD completed malignancies comp